Tuesday, November 5, 2013

Johnson & Johnson to Pay $2.2 Billion in Plea Deal on Drug Marketing

Pharmaceutical giant Johnson & Johnson will plead guilty to a criminal misdemeanor and pay $2.2 billion, thus concluding a long federal criminal investigation into the company's alleged marketing of certain antipsychotic drugs for off-label, unapproved uses, including allegations the drugs were promoted for use by the elderly with dementia. 

The original charges flow from whistleblower reports under the False Claims Act, involving Risperdal and other drugs.  Details of the deal are widely reported in the New York Times, Bloomberg and the Justice Department has issued a press release.   


Crimes, Health Care/Long Term Care, Medicare | Permalink

TrackBack URL for this entry:


Listed below are links to weblogs that reference Johnson & Johnson to Pay $2.2 Billion in Plea Deal on Drug Marketing:


Post a comment